TY  - JOUR
AU  - Rizzo, Manfredi
AU  - Abate, Nicola
AU  - Chandalia, Manisha
AU  - Rizvi, Ali A.
AU  - Giglio, Rosaria V.
AU  - Nikolić, Dragana
AU  - Gammazza, Antonella Marino
AU  - Barbagallo, Ignazio
AU  - Isenović, Esma R.
AU  - Banach, Maciej
AU  - Montalto, Giuseppe
AU  - Volti, Giovanni Li
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/508
AB  - Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; meanage: 57 +/- 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded. Main Outcome Measure(s): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 were assessed. Results: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 +/- 0.4 vs 7.5 +/- 0.4%, P LT .0001). In addition, plasma ghrelin and glutathione concentrations increased (8.2 +/- 4.1 vs 13.6 +/- 7.3 pg/ml, P = .0007 and 0.36 +/- 0.06 vs 0.44 +/- 0.07 nmol/ml, P = .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 +/- 0.05 vs 0.04 +/- 0.07 pg/ml, P = .0487 and 7.7 +/- 7.7 vs 3.6 +/- 1.8 pg/ml, P = .0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings seemed to be independent of the known effects of liraglutide on glucose metabolism.
T2  - Journal of Clinical Endocrinology and Metabolism
T1  - Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study
VL  - 100
IS  - 2
SP  - 603
EP  - 606
DO  - 10.1210/jc.2014-2291
ER  - 

@article{
author = "Rizzo, Manfredi and Abate, Nicola and Chandalia, Manisha and Rizvi, Ali A. and Giglio, Rosaria V. and Nikolić, Dragana and Gammazza, Antonella Marino and Barbagallo, Ignazio and Isenović, Esma R. and Banach, Maciej and Montalto, Giuseppe and Volti, Giovanni Li",
year = "2015",
abstract = "Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; meanage: 57 +/- 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded. Main Outcome Measure(s): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 were assessed. Results: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 +/- 0.4 vs 7.5 +/- 0.4%, P LT .0001). In addition, plasma ghrelin and glutathione concentrations increased (8.2 +/- 4.1 vs 13.6 +/- 7.3 pg/ml, P = .0007 and 0.36 +/- 0.06 vs 0.44 +/- 0.07 nmol/ml, P = .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 +/- 0.05 vs 0.04 +/- 0.07 pg/ml, P = .0487 and 7.7 +/- 7.7 vs 3.6 +/- 1.8 pg/ml, P = .0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings seemed to be independent of the known effects of liraglutide on glucose metabolism.",
journal = "Journal of Clinical Endocrinology and Metabolism",
title = "Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study",
volume = "100",
number = "2",
pages = "603-606",
doi = "10.1210/jc.2014-2291"
}

Rizzo, M., Abate, N., Chandalia, M., Rizvi, A. A., Giglio, R. V., Nikolić, D., Gammazza, A. M., Barbagallo, I., Isenović, E. R., Banach, M., Montalto, G.,& Volti, G. L.. (2015). Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study. in Journal of Clinical Endocrinology and Metabolism, 100(2), 603-606.
https://doi.org/10.1210/jc.2014-2291

Rizzo M, Abate N, Chandalia M, Rizvi AA, Giglio RV, Nikolić D, Gammazza AM, Barbagallo I, Isenović ER, Banach M, Montalto G, Volti GL. Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study. in Journal of Clinical Endocrinology and Metabolism. 2015;100(2):603-606.
doi:10.1210/jc.2014-2291 .

Rizzo, Manfredi, Abate, Nicola, Chandalia, Manisha, Rizvi, Ali A., Giglio, Rosaria V., Nikolić, Dragana, Gammazza, Antonella Marino, Barbagallo, Ignazio, Isenović, Esma R., Banach, Maciej, Montalto, Giuseppe, Volti, Giovanni Li, "Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study" in Journal of Clinical Endocrinology and Metabolism, 100, no. 2 (2015):603-606,
https://doi.org/10.1210/jc.2014-2291 . .

TY  - JOUR
AU  - Abate, Nicola
AU  - Sallam, Hanaa S.
AU  - Rizzo, Manfredi
AU  - Nikolić, Dragana
AU  - Obradović, Milan M.
AU  - Bjelogrlic, Predrag
AU  - Isenović, Esma R.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/56
AB  - Resistin is an adipocyte-and monocyte-derived cytokine which has been implicated in the modulation of insulin action, energy, glucose and lipid homeostasis. Resistin has been associated with insulin resistance and many of its known complications. As a molecular link between metabolic signals, inflammation, and vascular dysfunction, resistin can be proposed as playing a significant role in the heightened inflammatory state induced by metabolic stress linked to excessive caloric intake, thus contributing to the risk for metabolic syndrome (MetS), type 2 diabetes (T2DM), and cardiovascular diseases (CVD). In this review, we highlighted the role of resistin, as an inflammatory cytokine, in the development of CVD, T2DM and the MetS.
T2  - Current Pharmaceutical Design
T1  - Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
VL  - 20
IS  - 31
SP  - 4961
EP  - 4969
UR  - https://hdl.handle.net/21.15107/rcub_vinar_56
ER  - 

@article{
author = "Abate, Nicola and Sallam, Hanaa S. and Rizzo, Manfredi and Nikolić, Dragana and Obradović, Milan M. and Bjelogrlic, Predrag and Isenović, Esma R.",
year = "2014",
abstract = "Resistin is an adipocyte-and monocyte-derived cytokine which has been implicated in the modulation of insulin action, energy, glucose and lipid homeostasis. Resistin has been associated with insulin resistance and many of its known complications. As a molecular link between metabolic signals, inflammation, and vascular dysfunction, resistin can be proposed as playing a significant role in the heightened inflammatory state induced by metabolic stress linked to excessive caloric intake, thus contributing to the risk for metabolic syndrome (MetS), type 2 diabetes (T2DM), and cardiovascular diseases (CVD). In this review, we highlighted the role of resistin, as an inflammatory cytokine, in the development of CVD, T2DM and the MetS.",
journal = "Current Pharmaceutical Design",
title = "Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome",
volume = "20",
number = "31",
pages = "4961-4969",
url = "https://hdl.handle.net/21.15107/rcub_vinar_56"
}

Abate, N., Sallam, H. S., Rizzo, M., Nikolić, D., Obradović, M. M., Bjelogrlic, P.,& Isenović, E. R.. (2014). Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome. in Current Pharmaceutical Design, 20(31), 4961-4969.
https://hdl.handle.net/21.15107/rcub_vinar_56

Abate N, Sallam HS, Rizzo M, Nikolić D, Obradović MM, Bjelogrlic P, Isenović ER. Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome. in Current Pharmaceutical Design. 2014;20(31):4961-4969.
https://hdl.handle.net/21.15107/rcub_vinar_56 .

Abate, Nicola, Sallam, Hanaa S., Rizzo, Manfredi, Nikolić, Dragana, Obradović, Milan M., Bjelogrlic, Predrag, Isenović, Esma R., "Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome" in Current Pharmaceutical Design, 20, no. 31 (2014):4961-4969,
https://hdl.handle.net/21.15107/rcub_vinar_56 .